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CLINICAL CASE SEMINAR
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Malignant prolactinomas are extremely rare (1, 2). The di-
agnosis of these carcinomas is mainly based on the patient’s
medical history and the detection of metastases. Nuclear
medicine offers new imaging modalities for the detection of
metastases of pituitary carcinomas. These techniques may
have serious consequences for subsequent investigations and
therapy. The case presented here shows the clinical behavior
of a malignant prolactinoma. The usefulness of dopamine D2
receptor scintigraphy for establishing the diagnosis and sub-
sequently directing the therapeutic approach is illustrated.
Case Report
A 43-yr-old man presented with a macroprolactinoma in
1984. He was operated on by a transfrontal approach in 1984
and by two transsphenoidal approaches in 1985. Postoper-
atively, serum PRL levels did not normalize. The patient
showed partial resistance to dopamine agonists; serum PRL
levels decreased from 212 mg/L (normal, ,20 mg/L) at base-
line to 57 mg/L with bromocriptine therapy. From 1984–
1991, a progressive rise in serum PRL levels was noted de-
spite treatment with high doses of bromocriptine (55 mg/
day) and thereafter quinagolide (0.8 mg/day). When he was
referred to us in 1991, his serum PRL level was 757 mg/L on
quinagolide and 1575 mg/L without treatment. Pituitary
magnetic resonance imaging (MRI) showed a pituitary mac-
roadenoma with bilateral extrasellar extension to the cav-
ernous sinuses. Surgery was repeated using a transcranial
approach. However, postoperative serum PRL values re-
mained elevated (2181 mg/L). External pituitary irradiation
was administered (total dose, 5000 rads), and treatment with
cabergoline was started. From 1991–1993, a progressive de-
crease in PRL levels was observed (to 84 mg/L) while the
patient was still being treated with cabergoline (2.0 mg every
2 days). After this period of relative efficacy of this drug, a
progressive rise in serum PRL levels was observed again. The
patient was then treated four times with g-knife radiosurgery
(in 1994, 1995, 1996, and 1997). The last g-knife treatments
were less effective than the first ones (Fig. 1). The patient
underwent two additional pituitary explorations in 1997 and
1998 via the transcranial route in another center, which did
not reveal further tumorous tissue. He was then referred
back to us. At the last hospital admission (July 1998), 2
months after the last operation and discontinuation of caber-
goline treatment, serum PRL levels were much higher than
previously observed (7163 mg/L). Nevertheless, MRI study
did not reveal important tumor residue. Because the clinical
evolution of the patient strongly suggested a malignant pro-
lactinoma, nuclear imaging studies were performed.
Imaging studies
Dopamine D2 receptor scintigraphy. Epidepride scintigraphy
was performed as recently described (2). Potassium iodide
(100 mg daily) was administered for 5 days, starting 24 h
before radiopharmaceutical injection. [123I]Epidepride was
obtained from Dr. Angelberger, Osterreichisches Forschun-
gszentrum Seibersdorf GmbH (Seibersdorf, Austria), and
was distributed by IDB Holland BV (Baarle-Nassau, The
Netherlands). [123I]Epidepride (185 megabecquerels) was ad-
ministered iv, and images were obtained after 3 h. Single
photon emission computed tomography images of the head
were obtained using a three-headed camera (Picker 3000 xp,
Picker International, Cleveland, OH) equipped with a me-
dium energy collimator. The pulse height analyzer was cen-
tered over the energy peak (159 keV); the window width was
20%. Acquisition parameters were one scan, 36 s/frame, 120
projections, 360° rotation, 64 3 64 matrix. Images were re-
constructed using a Metz filter. Whole body images (from
head to upper legs) were obtained using a two-headed cam-
era (Prism 2000, Picker International). Acquisition time was
40 min. There was no uptake of [123I]epidepride in the pi-
tuitary region. Faint uptake that could correspond to a tumor
remnant was noticed close to the basal ganglia (Fig. 2). At
whole body imaging, normal uptake was seen in the urinary
bladder, liver, gall bladder, intestines, and lung. However,
pathological uptake was seen caudal in the left thorax (pos-
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sibly a rib), at multiple sites in the lower thoracic and lumbar
spine, and in the mediastinum and right femur (Fig. 3).
MRI. Total spine MRI was performed using T2 before gad-
olinium injection and T1 weighted images before and after
gadolinium injection. Multiple lesions suggestive of metas-
tases were seen along the thoracic (T1, T3, T5, T6, T7, T8, T10,
and T12) and lumbar vertebrae (L1, L2, L4, and L5; Fig. 4).
Clinical follow-up
Considering the nature and the extent of the metastatic
lesions, further palliative treatment was decided. Cabergo-
line was restarted despite its ineffectiveness in normalizing
serum PRL levels. However, a significant decrease in serum
PRL levels was observed again, and we hoped that this
treatment might also slow down tumor progression. Local
external radiotherapy was applied to the back to prevent
pain and peripheral nerve palsy.
Discussion
Pituitary carcinoma is one of the traps presenting to en-
docrinologists. These tumors are very rare, and a review of
the literature only reveals 96 cases (for 2 recent reviews, see
Refs. 1 and 2), which included 28 malignant prolactinomas
(1, 3–20), 25 ACTH-producing carcinomas, 12 GH-producing
carcinomas, 1 TSH-producing carcinoma, and 30 gonado-
tropin-producing or clinically nonfunctioning carcinomas
(2). At the University Hospital of Liege, this was the first
pituitary carcinoma among 1200 pituitary tumors.
The distinction between carcinomas and invasive adeno-
mas is difficult. Malignant prolactinomas do not present with
distinct clinical signs that distinguish them from benign tu-
mors. Initially, the radiological appearance may mimic that
of an adenoma. Histological examination, even using tumor
markers, does not allow easy differentiation between ade-
nomas and well differentiated carcinomas. The diagnosis is
usually suspected because of multiple recurrences and pro-
gressive inefficacy of treatment. However, these features can
also occur in drug-resistant and aggressive adenomas. There-
fore, the final diagnosis is often made after metastases have
been discovered.
In the present case, the early clinical features were com-
patible with a recurrent adenoma. gKnife radiotherapy was
very efficient at first. The loss of efficacy of radiotherapy and
radiosurgery in the later stages of the disease was attributed
to either resistance or increasing aggressiveness of the tumor.
However, retrospectively, this probably was the first man-
ifestation of extracranial metastases that were not yet sus-
pected and, therefore, not treated at that time. This hypoth-
esis is supported by the fact that at the last two operations
no tumor remnants were found in the sellar region. The
persistence of increased serum PRL levels despite dopamine
agonist therapy, the lack of efficacy of additional radiother-
apy, and the finding of an empty sella at surgery led to the
search for metastases.
FIG. 1. Evolution of PRL levels.
Quinagolide doses do not appear in the
graph due to the scale used to represent
the entire biological history. RxTh, Ra-
diotherapy.
FIG. 2. Coronal slices from the sellar region during epidepride scin-
tigraphy. Slices run from dorsal to ventral. Intense uptake in the
basal ganglia and slightly increased uptake below the left basal gan-
glion are shown.
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Malignant prolactinomas usually metastasize to the cen-
tral nervous system and arachnoidal tissues. Distant me-
tastases are rare. However, they have been reported in the
skeleton in two cases (1, 3), in lymph nodes in four cases
(1, 12, 18), in the lung in two cases (11, 13), and in the liver or
ovaries in three cases (1, 11, 16). Some researchers suggest that
metastases may have been grafted by surgery because they
have been found on the surgical route in some cases (16).
Scintigraphy can sometimes be very useful for demonstrat-
ing metastases and, therefore, for the confirmation of the ma-
lignant character of a tumor. Somatostatin receptor imaging has
been reported to be useful for the detection of metastatic de-
posits in a GH-secreting carcinoma (21). The use of this tech-
nique in a case of a malignant prolactinoma may be worthwhile,
because PRL-secreting cells may have somatostatin receptors.
However, these cells usually possess somatostatin receptor sub-
type 5 (sst5) (22), whereas [
111In]pentetreotide binds with high
affinity to somatostatin receptor subtype 2 (sst2) and with only
moderate to low affinity to sst5. Therefore, [
123I]epidepride, a
radioisotope with high affinity for D2 receptors, was used (23).
[123I]Epidepride scintigraphy finally revealed areas of patho-
logical uptake corresponding to extracranial metastases. This is
the first case in the literature in which D2 receptor imaging
demonstrated extracranial metastases of a pituitary carcinoma.
This technique may prove useful in future difficult cases, es-
pecially when dopamine D2 receptors instead of high affinity
somatostatin receptors are likely to be present in the tumor,
such as prolactinomas or their malignant counterparts.
Pathological examination of malignant prolactinomas
reveals only a slight degree of cytological atypia. Mitotic
activity is higher, and the tumor cells are usually aneu-
ploid. Labeling indexes for proliferation markers MIB-1
and proliferating cell nuclear antigen are higher in pri-
mary and metastatic tumors than in adenomatous cells.
FIG. 3. Total body scintigraphy 3 h after the injection of [123I]epidepride. Normal accumulation of radioactivity in the basal ganglia, thyroid,
lungs, liver, bowel, and urinary bladder in a control patient (left images are anterior and posterior views, respectively). Pathological uptake
projecting over the left anterior thorax, possibly in a rib (third image from left), and in multiple sites in the spine and right femur (rightmost
image) in the study patient.
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There is also a greater expression of p53 protein in these
cells (1). Little is known about the tumorigenesis of pituitary
carcinomas. Loss of retinoblastoma susceptibility gene has been
demonstrated in an ACTH-secreting pituitary carcinoma (24).
In another study, no mutations were detected in the p53 tumor
suppressor gene or in N- or K-ras G-protooncogenes, but point
mutations were identified in the H-ras gene (25).
The midterm evolution of patients presenting with PRL-
secreting carcinomas is pejorative. Only 50% of the cases de-
scribed in the literature showed a survival of more than 1 yr.
Surgery may be useful in debulking the lesion and relieving the
local compression effect. However, it cannot be repeated in-
definitely despite the recurrence of the tumor. Dopamine ago-
nists are widely used in the treatment of prolactinomas. In the
case of malignant tumors, they may slightly reduce the tumor
size, but without changing the final outcome. Some researchers
have used cytotoxic chemotherapy with a transient improve-
ment in the illness. The treatment consisted of different com-
binations of procarbazine, vincristine, etoposide, cisplatine, and
lomustine. The use of tamoxifen alone has been successful in
one case (16). Radiotherapy remains one of the more efficient
treatments. Despite the lack of a definite cure, it can be helpful
either in partly relieving the local complications of the tumor or
as a palliative treatment for pain.
Note Added in Proof
The patient presented in this case died in September 1999. The last
PRL level measured before his death was 45,500 mg/L.
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FIG. 4. Sagittal T1 spin echo sequences with gadolinium showing
hyperintensities involving the body of T5 and T6, the left pedicle of
T10, the T12 processus spinosus, and the body of L2 corresponding to
metastases. A, Median slices (left); B, left lateral slices (right).
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